Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadovist in newly diagnosed breast cancer
NCT01067976Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of gadobutrol in breast cancer, sponsored by Bayer. Primary endpoints: Sensitivity for Detection of Malignant Breast Disease and Specificity for Detection of Malignant Breast Disease. Started Feb 2010; status: completed.
02
Drugs
gadobutrol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01067976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01067976.